We caught up with Dr James Alexander (Imperial College London, London, UK) to discuss the impact of immunosuppressant drugs on COVID-19 vaccine responses in patients with IBD.
The abstract ‘COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab’ (Presentation no. OP21) was presented at the 17th Congress of ECCO, February 16-19, 2022!
Questions
- What was known about the impact of immunosuppressant drugs on COVID-19 vaccine-induced antibody responses in patients with IBD? (0:14)
- What were the aims and methodology of your study? (1:55)
- What were the study findings? (3:14)
- On the basis of these data, what are your recommendations for vaccines in IBD patients taking immunosuppressant drugs? (4:33)
Disclosures: James Alexander discloses receiving grant/ research support from Pfizer Ltd.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual meeting 2022.
